{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:35:42Z","timestamp":1789263342693,"version":"build-2803163510"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04266-z","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T10:14:58Z","timestamp":1747822498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of health insurance delays on biologic therapy access in autoimmune bullous disease: a single-center retrospective analysis"],"prefix":"10.1007","volume":"317","author":[{"given":"Paige E.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise K.","family":"Brunsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Rezania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Yale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T.","family":"Amber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"5","key":"4266_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1067\/mjd.2001.116339","volume":"45","author":"AR Ahmed","year":"2001","unstructured":"Ahmed AR (2001) Intravenous Immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45(5):679\u2013690","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"4266_CR2","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","volume":"355","author":"AR Ahmed","year":"2006","unstructured":"Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune Globulin. N Engl J Med 355(17):1772\u20131779","journal-title":"N Engl J Med"},{"key":"4266_CR3","doi-asserted-by":"publisher","first-page":"928621","DOI":"10.3389\/fimmu.2022.928621","volume":"13","author":"P Cao","year":"2022","unstructured":"Cao P, Xu W, Zhang L, Rituximab (2022) Omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: A systematic review. Front Immunol 13:928621","journal-title":"Front Immunol"},{"key":"4266_CR4","doi-asserted-by":"crossref","unstructured":"Constant BD, de Zoeten EF, Stahl MG et al (2022) Delays related to prior authorization in inflammatory bowel disease. Pediatrics 149(3)","DOI":"10.1542\/peds.2021-052501"},{"issue":"1","key":"4266_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2500\/aap.2021.42.200101","volume":"42","author":"GJ Dudiak","year":"2021","unstructured":"Dudiak GJ, Popyack J, Grimm C, Tyson S, Solic J, Ishmael FT (2021) Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations. Allergy Asthma Proc 42(1):65\u201371","journal-title":"Allergy Asthma Proc"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04266-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04266-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04266-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T10:15:00Z","timestamp":1747822500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04266-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4266"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04266-z","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Diana Silver is an employee at KabaFusion. Rebecca A. Strong and Marc Yale are employees of the International Pemphigus and Pemphigoid Foundation. Kyle T. Amber has received research support from Argenx, Astra Zeneca, Kabafusion. Paige E. Adams, Elise K. Brunsgaard, Nikki Rezania have no potential conflicts to report. Kyle T. Amber is supported by The Buntrock Fund for Bullous Pemphigoid Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"775"}}